Losartan for Patients With COVID-19 Not Requiring Hospitalization
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04311177|
Recruitment Status : Completed
First Posted : March 17, 2020
Results First Posted : May 4, 2022
Last Update Posted : May 4, 2022
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Corona Virus Infection Acute Respiratory Distress Syndrome SARS-CoV Infection||Drug: Losartan Other: Placebo||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||117 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization|
|Actual Study Start Date :||April 9, 2020|
|Actual Primary Completion Date :||February 1, 2021|
|Actual Study Completion Date :||February 1, 2021|
Participants in this arm will receive the study drug, Losartan.
Losartan; 25 mg daily; oral administration
Other Name: Cozaar
Placebo Comparator: Placebo
Participants in this arm will receive a placebo treatment.
Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration
- Percentage of Participants Admitted to the Hospital [ Time Frame: 15 days ]
Outcome reported as the percentage of participants per arm admitted to inpatient hospital care due to COVID-19-related disease within 15 days of randomization.
Currently, there is a pre-planned pooled analysis with a national trial network under development.
- Change in PROMIS Dyspnea Scale [ Time Frame: 10 days ]The PROMIS dyspnea scale consists of 4 subscales. 3 (1. general shortness of breath, 2. intensity, and 3. Frequency) are scored from 0 (no symptoms) to 10 (most severe). The 4th subscale is scored from 0-4 in response to the question "I've been short of breath" with 0 representing none and 4 the most severe, for a total range of 0-34. Results are difference between enrollment and day 10. There are no units.
- Change in SF-12 Physical Composite Score [ Time Frame: 10 days ]The SF-12 is a self-reported validated outcome measure assessing the impact of health on an individual's everyday life. Patients fill out a 12 question survey which is then scored by a clinician or researcher. Physical score is computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health. The 33-item Severity bank assesses the severity of difficulty breathing during various specific activities (the same 33 activities assessed in Dyspnea Functional Limitations). Each activity is rated in terms of degree of dyspnea (0 = no shortness of breath, 1 = mildly short of breath, 2 = moderately short of breath, 3 = severely short of breath) while engaging in the activity over the past 7 days. Total scores range from 0 to 99 with higher scores reflecting greater levels of dyspnea during daily activity.
- Change in SF-12 Mental Composite Score [ Time Frame: 10 days ]The SF-12 is a self-reported validated outcome measure assessing the impact of health on an individual's everyday life. Patients fill out a 12 question survey which is then scored by a clinician or researcher. Mental composite score is computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.
- Daily Maximum Temperature [ Time Frame: 10 days ]Participants will report their maximum daily oral temperature to the study team. Outcome is reported as the mean maximum daily body temperature (in degrees Celsius) over 10 days.
- Count of Participants With an Emergency Department or Clinic Presentation [ Time Frame: 28 days ]Outcome is reported as the mean number of emergency department and clinic presentations combined per participant in each arm.
- Disease Severity Rating Day 15 [ Time Frame: 15 days ]Outcome reported as the number of participants in each arm who fall into each of 7 categories. Lower scores indicate greater condition severity. The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities.
- Change in Viral Load by Nasopharyngeal Swab at Day 9 [ Time Frame: 9 days ]Viral load is measured as number of viral genetic copies per mL.
- Change in Viral Load by Nasopharyngeal Swab at Day 15 [ Time Frame: 15 days ]Viral load is measured as number of viral genetic copies per mL.
- Percentage of Patients Admitted to the Intensive Care Unit Within 15 Days [ Time Frame: 15 days ]Outcome reported as the percent of participants in each arm who require ICU admission by day 15 following randomization.
- Need for Oxygen Therapy at 15 Days [ Time Frame: 15 days ]Outcome reported as the percent of participants in each arm who require oxygen therapy by day 15 following randomization.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Positive laboratory test for COVID-19 based on local laboratory standard
- Age greater than or equal to 18 years of age
- One of the following: Upper respiratory symptoms (cough, rhinorrhea) or fever (>101.5) or loss of taste / smell
- Randomization > 72 hours of meeting inclusion criteria
- Randomization > 7 days of symptom onset
- Currently taking an angiotensin converting enzyme inhibitor (ACEi) or Angiotensin receptor blocker (ARB)
- Prior reaction or intolerance to an ARB or ACE inhibitor, including but not limited to angioedema
- Pregnant or breastfeeding women
- Females able to have children not currently taking a protocol allowed version of contraception: intrauterine device, Depo-formulation of hormonal contraception (e.g. medroxyprogesterone acetate/Depo-Provera), subcutaneous contraceptive (e.g. Nexplanon), daily oral contraceptives with verbalized commitment to taking daily throughout the study, condom use or abstinence during the study. All participants of child bearing potential enrolled in this fashion will be informed of the teratogenic risks.
Patient reported history or electronic medical record history of kidney disease, defined as:
- Any history of dialysis
- History of chronic kidney disease stage IV
- Estimated Glomerular Filtration Rate (eGFR) of < 30ml/min/1.73 m2 (must be have been measured within 1 month of enrollment)
- Other kidney disease that in the opinion of the investigator, would affect losartan clearance
- Patient reported dehydration and significantly decreased urine output in the past 72 hours
- Most recent systolic blood pressure prior to enrollment <110 mmHg
Patient reported history or electronic medical record history of severe liver disease, defined as:
- History of hepatitis B or C
- Other liver disease that in the opinion of the investigator, would affect losartan clearance
- Documented AST or ALT > 3 times the upper limit of normal within 3 months of randomization (if available in electronic medical record)
- Potassium >5.0 mmol/L (must have been measured within 1 month) of enrollment
- Concurrent treatment with aliskiren
- Inability to obtain informed consent
- Enrollment in another blinded randomized clinical trial for COVID
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04311177
|United States, Minnesota|
|Hennepin County Medical Center|
|Minneapolis, Minnesota, United States, 55415|
|M Health Fairview University of Minnesota Medical Center|
|Minneapolis, Minnesota, United States, 55455|
|University of Minnesota|
|Minneapolis, Minnesota, United States, 55455|
|Mayo Clinic Health System|
|Rochester, Minnesota, United States, 55415|
|Principal Investigator:||Christopher Tignanelli, MD||University of Minnesota|
|Principal Investigator:||Michael Puskarich, MD, MS||University of Minnesota|
Documents provided by University of Minnesota:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
|Responsible Party:||University of Minnesota|
|Other Study ID Numbers:||
|First Posted:||March 17, 2020 Key Record Dates|
|Results First Posted:||May 4, 2022|
|Last Update Posted:||May 4, 2022|
|Last Verified:||May 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
|Product Manufactured in and Exported from the U.S.:||No|
Respiratory Distress Syndrome
Respiratory Distress Syndrome, Newborn
Acute Lung Injury
Respiratory Tract Infections
RNA Virus Infections
Respiratory Tract Diseases
Infant, Premature, Diseases
Infant, Newborn, Diseases
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action